MCID: WSK001
MIFTS: 77

Wiskott-Aldrich Syndrome

Categories: Genetic diseases, Rare diseases, Immune diseases, Skin diseases, Blood diseases

Aliases & Classifications for Wiskott-Aldrich Syndrome

MalaCards integrated aliases for Wiskott-Aldrich Syndrome:

Name: Wiskott-Aldrich Syndrome 57 38 12 25 59 75 37 29 13 13 55 6 44 15 40 73
Eczema-Thrombocytopenia-Immunodeficiency Syndrome 57 25 59 75
Immunodeficiency 2 57 53 25 75
Was 57 53 59 75
Aldrich Syndrome 57 53 75
Imd2 57 25 75
Wiskott-Aldrich Syndrome 1 57 75
Wiskott Syndrome 12 25
Was1 57 75
Eczema Thrombocytopenia Immunodeficiency Syndrome 53
Wiskott-Aldrich Syndrome 1; Was1 57
Immunodeficiency 2; Imd2 57
Wiskott Aldrich Syndrome 53
Imd 2 53

Characteristics:

Orphanet epidemiological data:

59
wiskott-aldrich syndrome
Inheritance: Autosomal dominant,Autosomal recessive,Not applicable,X-linked recessive; Prevalence: 1-9/1000000 (Europe),1-9/1000000 (France); Age of onset: Infancy,Neonatal; Age of death: any age;

OMIM:

57
Inheritance:
x-linked recessive


HPO:

32
wiskott-aldrich syndrome:
Inheritance x-linked recessive inheritance


Classifications:



Summaries for Wiskott-Aldrich Syndrome

NIH Rare Diseases : 53 Wiskott Aldrich syndrome (WAS) is a disease with immunological deficiency and reduced ability to form blood clots. Signs and symptoms include easy bruising or bleeding due to a decrease in the number and size of platelets; susceptibility to infections and to immune and inflammatory disorders; and an increased risk for some cancers (such as lymphoma).  Also, a skin condition known as eczema is common in  people with WAS. Wiskott Aldrich syndrome  is caused by mutations in the WAS gene and is inherited in an X-linked manner. It primarily affects males. Treatment may depend on severity and symptoms in each person, but hematopoietic cell transplantation is the only known cure.  Hematopoietic cells are the blood-forming stem cells that can be found mainly in the sponge-like material found inside bones (bone marrow), but also in the bloodstream (peripheral blood stem cells (PBSCs),  and in the umbilical cord.Prognosis have improved over time due to better management of the disease. People who have a successful and uncomplicated hematopoeitic cell transplantation, usually have normal immune function and, normal survival. Wiskott-Aldrich syndrome, X-linked thrombocytopenia (XLT), and X-linked neutropenia (XLN) are known as “WAS-related disorders” because these diseases are all caused by mutations in the WAS gene, and have overlapping symptoms ranging from severe to mild (Wiskott-Aldrich syndrome is the most severe).  The WAS gene mutations result in deficiency of the Wiskott-Aldrich syndrome protein (WASP). The more deficient the WASP, the more severe the disease.

MalaCards based summary : Wiskott-Aldrich Syndrome, also known as eczema-thrombocytopenia-immunodeficiency syndrome, is related to agammaglobulinemia, x-linked and wiskott-aldrich syndrome 2, and has symptoms including diarrhea and petechiae of skin. An important gene associated with Wiskott-Aldrich Syndrome is WAS (Wiskott-Aldrich Syndrome), and among its related pathways/superpathways are Endocytosis and Regulation of actin cytoskeleton. The drugs Dexmedetomidine and Benzocaine have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and bone marrow, and related phenotypes are sudden cardiac death and chronic otitis media

OMIM : 57 Wiskott-Aldrich syndrome (WAS) is an X-linked recessive immunodeficiency characterized by thrombocytopenia, eczema, and recurrent infections (Lemahieu et al., 1999). (301000)

UniProtKB/Swiss-Prot : 75 Wiskott-Aldrich syndrome: An X-linked recessive immunodeficiency characterized by eczema, thrombocytopenia, recurrent infections, and bloody diarrhea. Death usually occurs before age 10.

Genetics Home Reference : 25 Wiskott-Aldrich syndrome is characterized by abnormal immune system function (immune deficiency) and a reduced ability to form blood clots. This condition primarily affects males.

Wikipedia : 76 Wiskott–Aldrich syndrome (WAS) is a rare X-linked recessive disease characterized by eczema,... more...

Related Diseases for Wiskott-Aldrich Syndrome

Diseases in the Wiskott-Aldrich Syndrome family:

Wiskott-Aldrich Syndrome, Autosomal Dominant Form Wiskott-Aldrich Syndrome 2

Diseases related to Wiskott-Aldrich Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Related Disease Score Top Affiliating Genes
1 agammaglobulinemia, x-linked 29.6 BTK SRC WAS
2 wiskott-aldrich syndrome 2 12.7
3 wiskott-aldrich syndrome, autosomal dominant form 12.3
4 storage pool platelet disease 11.3
5 specific antibody deficiency 11.3
6 immunodeficiency, common variable, 2 10.9
7 thrombocytopenia 10.8
8 thrombocytopenia 1 10.7
9 lymphoma 10.6
10 hematopoietic stem cell transplantation 10.5
11 aneurysm 10.5
12 neuronitis 10.4
13 purpura 10.4
14 aortic aneurysm 10.3
15 herpes simplex 10.3
16 autoimmune lymphoproliferative syndrome, type v 10.3
17 glomerulonephritis 10.3
18 colitis 10.3
19 type i 10.3
20 spinocerebellar ataxia, autosomal recessive 1 10.2 WAS WASF1 WASL
21 aortic aneurysm, familial thoracic 1 10.2
22 dermatitis 10.2
23 iga glomerulonephritis 10.2
24 vasculitis 10.2
25 cytomegalovirus infection 10.2
26 hepatocellular carcinoma 10.1
27 ovarian cancer 10.1
28 lymphoma, hodgkin, classic 10.1
29 dermatitis, atopic 10.1
30 lymphoma, non-hodgkin, familial 10.1
31 juvenile myelomonocytic leukemia 10.1
32 b-cell lymphomas 10.1
33 leukemia 10.1
34 lymphomatoid granulomatosis 10.1
35 neutropenia 10.1
36 thrombotic thrombocytopenic purpura 10.1
37 sarcoma 10.1
38 sclerosing cholangitis 10.1
39 hyperostosis 10.1
40 progressive multifocal leukoencephalopathy 10.1
41 thyroiditis 10.1
42 cholangitis 10.1
43 alzheimer disease 10.0
44 burkitt lymphoma 10.0
45 breast cancer 10.0
46 renal cell carcinoma, nonpapillary 10.0
47 intussusception 10.0
48 systemic lupus erythematosus 10.0
49 lung cancer 10.0
50 fanconi anemia, complementation group a 10.0

Graphical network of the top 20 diseases related to Wiskott-Aldrich Syndrome:



Diseases related to Wiskott-Aldrich Syndrome

Symptoms & Phenotypes for Wiskott-Aldrich Syndrome

Symptoms via clinical synopsis from OMIM:

57
Genitourinary Kidneys:
nephropathy

Head And Neck Head:
sinusitis

Skin Nails Hair Skin:
purpura
eczema
petechiae

Head And Neck Ears:
otitis media

Neurologic Central Nervous System:
meningitis

Respiratory Lung:
pneumonia

Head And Neck Mouth:
oral bleeding

Hematology:
hemolytic anemia
thrombocytopenia
iron deficiency anemia
small platelets size
small and large vessel vasculitis
more
Immunology:
lymphopenia
moderately depressed antibody response to polysaccharide antigens
abnormal delayed hypersensitivity skin test
absent microvilli on the surface of peripheral blood lymphocytes

Abdomen Gastrointestinal:
diarrhea
hematemesis
melena
inflammatory bowel disease

Head And Neck Nose:
epistaxis

Laboratory Abnormalities:
prolonged bleeding time
increased ige levels
reduced igm levels
normal igg levels
increased iga levels
more
Respiratory Airways:
upper respiratory tract infections
lower respiratory tract infections


Clinical features from OMIM:

301000

Human phenotypes related to Wiskott-Aldrich Syndrome:

59 32 (show top 50) (show all 74)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 sudden cardiac death 59 32 occasional (7.5%) Occasional (29-5%) HP:0001645
2 chronic otitis media 59 32 hallmark (90%) Very frequent (99-80%) HP:0000389
3 arthritis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001369
4 recurrent respiratory infections 59 32 hallmark (90%) Very frequent (99-80%) HP:0002205
5 nephropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0000112
6 fever 59 32 hallmark (90%) Very frequent (99-80%) HP:0001945
7 fatigue 59 32 frequent (33%) Frequent (79-30%) HP:0012378
8 dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002094
9 immunodeficiency 59 32 hallmark (90%) Very frequent (99-80%) HP:0002721
10 hemolytic anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001878
11 peripheral neuropathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0009830
12 sinusitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0000246
13 specific learning disability 59 32 frequent (33%) Frequent (79-30%) HP:0001328
14 autoimmunity 59 32 frequent (33%) Frequent (79-30%) HP:0002960
15 inflammation of the large intestine 59 32 frequent (33%) Frequent (79-30%) HP:0002037
16 thrombocytopenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001873
17 microcytic anemia 59 32 frequent (33%) Frequent (79-30%) HP:0001935
18 skin ulcer 59 32 occasional (7.5%) Occasional (29-5%) HP:0200042
19 spontaneous hematomas 59 32 hallmark (90%) Very frequent (99-80%) HP:0007420
20 glomerulopathy 59 32 occasional (7.5%) Occasional (29-5%) HP:0100820
21 keratitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000491
22 blepharitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000498
23 chronic obstructive pulmonary disease 59 32 hallmark (90%) Very frequent (99-80%) HP:0006510
24 lymphopenia 59 32 hallmark (90%) Very frequent (99-80%) HP:0001888
25 hypoplasia of the thymus 59 32 occasional (7.5%) Occasional (29-5%) HP:0000778
26 chest pain 59 32 occasional (7.5%) Occasional (29-5%) HP:0100749
27 otitis media 59 32 Very frequent (99-80%) HP:0000388
28 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
29 conjunctivitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000509
30 meningitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0001287
31 neutropenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001875
32 chronic diarrhea 59 32 hallmark (90%) Very frequent (99-80%) HP:0002028
33 sepsis 59 32 occasional (7.5%) Occasional (29-5%) HP:0100806
34 abnormality of the menstrual cycle 59 32 occasional (7.5%) Occasional (29-5%) HP:0000140
35 bruising susceptibility 59 32 hallmark (90%) Very frequent (99-80%) HP:0000978
36 gingival bleeding 59 32 occasional (7.5%) Occasional (29-5%) HP:0000225
37 eczema 59 32 occasional (7.5%) Occasional (29-5%) HP:0000964
38 petechiae 59 32 frequent (33%) Frequent (79-30%) HP:0000967
39 urticaria 59 32 occasional (7.5%) Occasional (29-5%) HP:0001025
40 intracranial hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0002170
41 hematemesis 59 32 frequent (33%) Frequent (79-30%) HP:0002248
42 acute leukemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002488
43 hematochezia 59 32 frequent (33%) Frequent (79-30%) HP:0002573
44 vasculitis 59 32 occasional (7.5%) Occasional (29-5%) HP:0002633
45 lymphoma 59 32 occasional (7.5%) Occasional (29-5%) HP:0002665
46 prolonged bleeding time 59 32 hallmark (90%) Very frequent (99-80%) HP:0003010
47 chronic leukemia 59 32 occasional (7.5%) Occasional (29-5%) HP:0005558
48 recurrent intrapulmonary hemorrhage 59 32 occasional (7.5%) Occasional (29-5%) HP:0006535
49 abnormal platelet function 59 32 occasional (7.5%) Occasional (29-5%) HP:0011869
50 abnormal platelet morphology 59 32 hallmark (90%) Very frequent (99-80%) HP:0011875

UMLS symptoms related to Wiskott-Aldrich Syndrome:


diarrhea, petechiae of skin

GenomeRNAi Phenotypes related to Wiskott-Aldrich Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.7 FYN GRB2 NCK1 WASF3 ACTR3 BTK
2 Decreased cell migration GR00055-A-1 9.65 ACTR3 GRB2 NCK1 WASF1 WASL
3 Decreased Salmonella enterica Typhimurium ruffling GR00133-A-5 9.13 ACTR2 ACTR3 CDC42
4 Decreased Salmonella-containing vacuole maturation GR00133-A-2 8.8 ACTR2 ACTR3 CDC42

MGI Mouse Phenotypes related to Wiskott-Aldrich Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.36 WIPF1 BTK CTTN FYN GRB2 PSTPIP1

Drugs & Therapeutics for Wiskott-Aldrich Syndrome

Drugs for Wiskott-Aldrich Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 397)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
2
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
3
Zinc Approved, Investigational Phase 4 7440-66-6 23994
4
Ranibizumab Approved Phase 4,Phase 3 347396-82-1 459903
5
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 22916-47-8 4189
7
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 128794-94-5 5281078
8
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1 24280-93-1 446541
9
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 5284616 6436030 46835353
10
Diltiazem Approved, Investigational Phase 4,Phase 3 42399-41-7 39186
11
Pitavastatin Approved Phase 4 147511-69-1, 147526-32-7 6366718 5282452
12
Amlodipine Approved Phase 4 88150-42-9 2162
13
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
14
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
15
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
16
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
17
Dopamine Approved Phase 4,Phase 3,Not Applicable 51-61-6, 62-31-7 681
18
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
19
Norepinephrine Approved Phase 4 51-41-2 439260
20
Calcium acetate Approved, Investigational Phase 4 62-54-4
21
Sevelamer Approved Phase 4 52757-95-6
22
Dihydroartemisinin Approved, Investigational Phase 4 71939-50-9 6918483
23
Morphine Approved, Investigational Phase 4 57-27-2 5288826
24
Piperaquine Approved, Investigational Phase 4 4085-31-8 5079497
25
Primaquine Approved Phase 4 90-34-6 4908
26
Adefovir Dipivoxil Approved, Investigational Phase 4 142340-99-6 60871
27
Budesonide Approved Phase 4 51333-22-3 63006 5281004
28
Fluticasone Approved, Experimental, Investigational Phase 4 90566-53-3 62924
29
Glimepiride Approved Phase 4 93479-97-1 3476
30
Metformin Approved Phase 4,Phase 2,Phase 3 657-24-9 14219 4091
31
Ephedrine Approved Phase 4,Not Applicable 299-42-3 9294
32
Pseudoephedrine Approved Phase 4,Not Applicable 90-82-4 7028
33
Nicotine Approved Phase 4 54-11-5 942 89594
34
Carbidopa Approved Phase 4 28860-95-9 34359 38101
35
Levodopa Approved Phase 4 59-92-7 6047
36
Midodrine Approved Phase 4 133163-28-7, 42794-76-3 4195
37
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
38
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
39
Glucosamine Approved, Investigational, Nutraceutical Phase 4 3416-24-8 439213
40
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 2 59-67-6 938
41
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 2 98-92-0 936
42 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Not Applicable
43 Garlic Approved, Nutraceutical Phase 4
44
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
45
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3 50-14-6 5280793
46
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
47
Adefovir Investigational Phase 4 106941-25-7
48 Adrenergic Agents Phase 4,Not Applicable,Early Phase 1
49 Adrenergic Agonists Phase 4
50 Adrenergic alpha-2 Receptor Agonists Phase 4

Interventional clinical trials:

(show top 50) (show all 184)
# Name Status NCT ID Phase Drugs
1 Treatment Protocol of Child SAA With the Injection of Mesenchymal Stem Cells(Umbilical Cord Derived) Unknown status NCT02218437 Phase 4 MSC+ATG
2 The ED50 of DEX for Providing Sedation in Different Female Age Group Unknown status NCT02773017 Phase 4 Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
3 Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects Completed NCT00634569 Phase 4
4 A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency Completed NCT01289847 Phase 4
5 Effects of Glucosamine and Chondroitin Supplementation in Women With Knee Osteoarthritis Participating in an Exercise and Weight Loss Program Completed NCT01271218 Phase 4
6 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed NCT01148511 Phase 4 Ranibizumab 0.5 mg
7 Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients Completed NCT00121810 Phase 4 mycophenolate mofetil [CellCept];Corticosteroids;Calcineurin inhibitors;Sirolimus
8 Drug-Drug Interaction of Cardizem LA (Diltiazem Hydrochloride) on Pitavastatin Completed NCT01422382 Phase 4 Pitavastatin (NK-104);Diltiazem (Cardizem LA) 240 mg QD
9 Postpartum Women's Dexmedetomidine Sedation Completed NCT02111421 Phase 4 Dexmedetomidine 01;Dexmetomidine 02
10 ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria Completed NCT01375322 Phase 4 Amlodipine+Benazepril;Valsartan+Hydrochlorothiazide
11 Effect of Aged Garlic Extract on Atherosclerosis Completed NCT01534910 Phase 4 aged garlic extract;placebo
12 Study on Bone Marrow Morphology in Adults Receiving Romiplostim for Treatment of Thrombocytopenia Associated With Immune Thrombocytopenia Purpura (ITP) Completed NCT00907478 Phase 4
13 The Influence of Age on Dexmedetomidine Pharmacodynamic Completed NCT02099253 Phase 4 Dexmedetomidine 01;Dexmedetomidine 02
14 Duloxetine Treatment in Elderly With Dysthymia Completed NCT01852383 Phase 4 Duloxetine
15 Sevelamer, FGF-23 and Endothelial Dysfunction in Chronic Kidney Disease (CKD) Completed NCT01135615 Phase 4 Sevelamer;calcium acetate
16 Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra Completed NCT01389557 Phase 4 Dihydroartemisinin-piperaquine with primaquine
17 Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis Completed NCT00347009 Phase 4 adefovir dipivoxil
18 Long-Term Immune Persistence of GlaxoSmithKline Biologicals' Inactivated Hepatitis A Vaccine Injected According to a 0, 12-month Schedule Completed NCT00291876 Phase 4
19 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
20 Paricalcitol Effect on Anemia in CKD Completed NCT01768351 Phase 4 Paricalcitol;Calcitriol
21 Efficacy and Safety of Sitagliptin/Metformin Fixed-Dose Combination (FDC) Compared to Glimepiride in Participants With Type 2 Diabetes Mellitus (MK-0431A-202) Completed NCT00993187 Phase 4 Sitagliptin/Metformin FDC;Comparator: Glimepiride;Matching placebo to Sitagliptin/Metformin FDC;Matching placebo to glimepiride
22 Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases Completed NCT01392014 Phase 4 dihydroartemisinin-piperaquine;dihydroartemisinin-piperaquine + primaquine
23 Treatment of CNV With Aflibercept Combined With Pranoprofen Eye Drops or Nutraceutical Support With Omega-3 Completed NCT03355638 Phase 4 Aflibercept Injection [Eylea];Pranoprofen Eyedrops;Omega-3 Supplementation
24 Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment Completed NCT00749463 Phase 4 Nicotine Gum;Nicotine Patch
25 Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic Impact Completed NCT00141518 Phase 4 Levodopa-carbidopa intestinal gel (LCIG)
26 Impact and Cost of a Pharmacist Pneumococcal Vaccination Program With PNEUMOVAX® 23 at an Urban Senior Center Completed NCT01944462 Phase 4
27 Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension Completed NCT00555880 Phase 4 Midodrine hydrochloride;Placebo
28 On-pump Beating Coronary Artery Bypass Grafting by Ventricular Assist Recruiting NCT02731794 Phase 4
29 Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases. Completed NCT00278954 Phase 3
30 An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy Completed NCT00883753 Phase 3 tocilizumab [RoActemra/Actemra]
31 Rapid Infusion of Immune Globulin Intravenous (Human) In Primary Immunodeficiency Patients Completed NCT00220766 Phase 3 Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified;Dextrose, 5% in Water
32 Topical Green Tea Ointment in Treatment of Superficial Skin Cancer Completed NCT02029352 Phase 2, Phase 3 Sinecatechins 10%;Placebo
33 A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults Completed NCT01196975 Phase 3
34 Safety and Efficacy of Dose Conversion From Vicodin® to Buprenorphine Transdermal System (Butrans™) in Subjects With OA Pain Completed NCT00312572 Phase 3 Buprenorphine transdermal patch
35 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Completed NCT00137969 Phase 2, Phase 3 Rituximab;Placebo;Prednisone;Acetaminophen;Diphenhydramine
36 Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs Completed NCT00866775 Phase 3 Eslicarbazepine acetate;Eslicarbazepine acetate
37 Safety & Efficacy of Eslicarbazepine Monotherapy in Sub.w/Partial Epilepsy Not Well Controlled by Current Antiepileptic Completed NCT01091662 Phase 3 Eslicarbazepine acetate 1600 mg;Eslicarbazepine acetate 1200 mg
38 Safety/Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Cysteamine Treatment Naive Patients With Cystinosis Completed NCT01744782 Phase 3 RP103
39 Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children Completed NCT01196988 Phase 3
40 Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO) Completed NCT00803634 Phase 3 Clevidipine;Standard of Care IV antihypertensive
41 Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A) Completed NCT01204671 Phase 3
42 Safety and Efficacy of Paricalcitol Capsules in Decreasing Serum Parathyroid Hormone Levels in Children Aged 10-16 With Chronic Kidney Disease (CKD) Completed NCT01020487 Phase 3 Paricalcitol;Placebo
43 Silicone Gel in the Treatment of Cleft Lip Scars Completed NCT03314090 Phase 3 Silicone Gels
44 A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin Completed NCT00734474 Phase 2, Phase 3 LY2189265;Sitagliptin;Placebo solution;Placebo tablet;Metformin
45 Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes Completed NCT00116831 Phase 3 Glipizide;rosiglitazone maleate
46 Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection Completed NCT01069900 Phase 3 Moxifloxacin (Avelox, BAY12-8039);Ertapenem;Amoxicillin/Clavulanate;Moxifloxacin placebo;Ertapenem placebo;Amoxicillin/Clavulanate placebo
47 Link Between the Sensitivity of Kisspeptin Signalling and Pubertal Onset in Boys. Completed NCT03286517 Phase 3
48 A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis. Completed NCT00377637 Phase 3 Mycophenolate mofetil (MMF);Cyclophosphamide;Azathioprine;Placebo to Azathioprine;Placebo to Mycophenolate mofetil;Corticosteroid
49 Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants Completed NCT00586612 Phase 3
50 A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis. Completed NCT00711646 Phase 3 Sativex®;Placebo

Search NIH Clinical Center for Wiskott-Aldrich Syndrome

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Wiskott-Aldrich Syndrome cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: wiskott-aldrich syndrome

Genetic Tests for Wiskott-Aldrich Syndrome

Genetic tests related to Wiskott-Aldrich Syndrome:

# Genetic test Affiliating Genes
1 Wiskott-Aldrich Syndrome 29 WAS

Anatomical Context for Wiskott-Aldrich Syndrome

MalaCards organs/tissues related to Wiskott-Aldrich Syndrome:

41
Bone, Skin, Bone Marrow, T Cells, B Cells, Eye, Kidney

Publications for Wiskott-Aldrich Syndrome

Articles related to Wiskott-Aldrich Syndrome:

(show top 50) (show all 684)
# Title Authors Year
1
Autoimmune thyroiditis following HLA-matched sibling hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome. ( 29761856 )
2018
2
Discovering the Cause of Wiskott-Aldrich Syndrome and Laying the Foundation for Understanding Immune Cell Structuring. ( 29784762 )
2018
3
Autonomous role of Wiskott-Aldrich Syndrome platelet deficiency in inducing autoimmunity and inflammation. ( 29421274 )
2018
4
Get Outta Here! Addition of Mobilizing Agents to Conditioning Regimen Improves Donor Engraftment after Allogeneic Hematopoietic Stem Cell Transplantation for Wiskott-Aldrich Syndrome. ( 29753160 )
2018
5
Somatic mutations activating Wiskott-Aldrich syndrome protein concomitant with RAS pathway mutations in juvenile myelomonocytic leukemia patients. ( 29316027 )
2018
6
Pillars Article: Isolation of a Novel Gene Mutated in Wiskott-Aldrich Syndrome. <i>Cell</i>. 1994. 78: 635-644. ( 29784763 )
2018
7
Unrelated umbilical cord stem cell transplantation in an eleven-month-old male infant with Wiskott-Aldrich syndrome. ( 29413229 )
2018
8
Posttransplant cyclophosphamide for haploidentical stem cell transplantation in children with Wiskott-Aldrich syndrome. ( 29745014 )
2018
9
Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. ( 29196934 )
2018
10
Neutrophils drive type-I interferon production and autoantibodies in Wiskott-Aldrich syndrome. ( 29447842 )
2018
11
Screening for Wiskott-Aldrich syndrome by flow cytometry. ( 29729304 )
2018
12
Neuropsychological Profile of a Girl with Wiskott-Aldrich Syndrome. ( 29561314 )
2018
13
Wiskott-Aldrich syndrome that was initially diagnosed as immune thrombocytopenic purpura secondary to a cytomegalovirus infection. ( 29348920 )
2018
14
Identification of Wiskott-Aldrich syndrome protein (WASP) binding sites on the branched actin filament nucleator Arp2/3 complex. ( 29386393 )
2018
15
MicroRNA-214-5p Inhibits the Invasion and Migration of Hepatocellular Carcinoma Cells by Targeting Wiskott-Aldrich Syndrome Like. ( 29621773 )
2018
16
A Conditioning Regimen with Plerixafor Is Safe and Improves the Outcome of TCRI+I^<sup>+</sup> and CD19<sup>+</sup> Cell-Depleted Stem Cell Transplantation in Patients with Wiskott-Aldrich Syndrome. ( 29550630 )
2018
17
Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome. ( 29086100 )
2018
18
The Wiskott-Aldrich Syndrome Protein Contributes to the Assembly of the LFA-1 Nanocluster Belt at the Lytic Synapse. ( 29386139 )
2018
19
Descending aortic aneurysm in Wiskott-Aldrich syndrome: options for repair. ( 29022827 )
2017
20
Comparison of ZFNs versus CRISPR specific nucleases for genome edition of the Wiskott-Aldrich Syndrome locus. ( 28922955 )
2017
21
Un-manipulated Haploidentical Transplant in Wiskott-Aldrich Syndrome. ( 28474594 )
2017
22
Intermittent low platelet counts hampering diagnosis of X-linked thrombocytopenia in children: report of two unrelated cases and a novel mutation in the gene coding for the Wiskott-Aldrich syndrome protein. ( 28641574 )
2017
23
Safe and Effective Gene Therapy for Murine Wiskott-Aldrich Syndrome Using an Insulated Lentiviral Vector. ( 28344987 )
2017
24
In Vivo Chronic Stimulation Unveils Autoreactive Potential of Wiskott-Aldrich Syndrome Protein-Deficient B Cells. ( 28512459 )
2017
25
Nuclear Wiskott-Aldrich syndrome protein co-regulates T cell factor 1-mediated transcription in T cells. ( 29078804 )
2017
26
Successful treatment of pyoderma gangrenosum with anakinra in a patient with Wiskott-Aldrich syndrome. ( 29214738 )
2017
27
Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome. ( 28232030 )
2017
28
Wiskott-Aldrich syndrome protein: Emerging mechanisms in immunity. ( 28805251 )
2017
29
R-loops cause genomic instability in T helper lymphocytes from patients with Wiskott-Aldrich syndrome. ( 29248492 )
2017
30
Successful Reduced Intensity Allogeneic Transplant With Full Donor Chimerism and Good Quality of Life in Adolescent Patient With Wiskott-Aldrich Syndrome. ( 28538502 )
2017
31
Low T Cell Numbers Resembling T-B+ SCID in a Patient with Wiskott-Aldrich Syndrome and the Outcome of Two Hematopoietic Stem Cell Transplantations. ( 27900584 )
2017
32
Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. ( 29196075 )
2017
33
Successful HLA haploidentical HSCT with post-transplant cyclophosphamide in Wiskott-Aldrich syndrome. ( 28287640 )
2017
34
Abnormal distribution of distinct lymphocyte subsets in children with Wiskott-Aldrich syndrome. ( 28535968 )
2017
35
A risk factor analysis of outcomes after unrelated cord blood transplantation for children with Wiskott-Aldrich syndrome. ( 28255019 )
2017
36
Wiskott-Aldrich Syndrome Misdiagnosed as Immune Thrombocytopenic Purpura: A Case Report. ( 28859046 )
2017
37
Childhood-onset inflammatory bowel diseases associated with mutation of Wiskott-Aldrich syndrome protein gene. ( 29358862 )
2017
38
50 Years Ago in The Journal of Pediatrics: Wiskott-Aldrich Syndrome: Clinical, Immunologic, and Pathologic Observations. ( 28129868 )
2017
39
Wiskott-Aldrich syndrome protein regulates autophagy and inflammasome activity in innate immune cells. ( 29146903 )
2017
40
Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult. ( 28716862 )
2017
41
Wiskott-Aldrich syndrome: Two case reports with a novel mutation. ( 29200320 )
2017
42
Activation of compensatory pathways via Rac2 in the absence of the Cdc42 effector Wiskott-Aldrich syndrome protein in Dendritic cells. ( 28129089 )
2017
43
Platelets in Wiskott-Aldrich syndrome: victims or executioners? ( 28851742 )
2017
44
Lung transplantation after haematopoietic stem cell transplantation for Wiskott-Aldrich syndrome. ( 29309544 )
2017
45
Neural Wiskott-Aldrich syndrome protein (nWASP) is implicated in human lung cancer invasion. ( 28351346 )
2017
46
Successful Reduced Intensity Conditioning Alternate Donor Stem Cell Transplant for Wiskott-Aldrich Syndrome. ( 28859032 )
2017
47
Eltrombopag use in a patient with Wiskott-Aldrich syndrome. ( 28643468 )
2017
48
Allergy in Wiskott-Aldrich syndrome. ( 27760100 )
2016
49
Wiskott-Aldrich Syndrome: Description of a New Gene Mutation Without Immunodeficiency. ( 26583625 )
2016
50
Successful Long-term Graft Survival of a Renal Transplantation Patient with Wiskott-Aldrich Syndrome. ( 27374679 )
2016

Variations for Wiskott-Aldrich Syndrome

UniProtKB/Swiss-Prot genetic disease variations for Wiskott-Aldrich Syndrome:

75 (show all 19)
# Symbol AA change Variation ID SNP ID
1 WAS p.Glu31Lys VAR_005825
2 WAS p.Ser82Pro VAR_005829 rs132630272
3 WAS p.Arg86His VAR_005830 rs132630268
4 WAS p.Arg86Leu VAR_005831 rs132630268
5 WAS p.Arg86Cys VAR_005832
6 WAS p.Trp97Cys VAR_005833
7 WAS p.Glu131Lys VAR_005834 rs146220228
8 WAS p.Glu133Lys VAR_005835
9 WAS p.Gly187Cys VAR_005836
10 WAS p.Lys476Glu VAR_005838
11 WAS p.Cys43Trp VAR_008105
12 WAS p.Thr45Met VAR_008106 rs132630273
13 WAS p.Cys73Arg VAR_008107
14 WAS p.Phe84Leu VAR_008109
15 WAS p.Gly89Asp VAR_008110 rs139857045
16 WAS p.Gln52His VAR_012710
17 WAS p.Gly70Trp VAR_012711
18 WAS p.Pro58Leu VAR_022806
19 WAS p.Ala134Thr VAR_022807

ClinVar genetic disease variations for Wiskott-Aldrich Syndrome:

6
(show top 50) (show all 54)
# Gene Variation Type Significance SNP ID Assembly Location
1 WAS WAS, 1-BP DEL, 211T deletion Pathogenic
2 WAS NM_000377.2(WAS): c.257G> T (p.Arg86Leu) single nucleotide variant Pathogenic rs132630268 GRCh37 Chromosome X, 48542796: 48542796
3 WAS NM_000377.2(WAS): c.257G> T (p.Arg86Leu) single nucleotide variant Pathogenic rs132630268 GRCh38 Chromosome X, 48684407: 48684407
4 WAS NM_000377.2(WAS): c.257G> A (p.Arg86His) single nucleotide variant Pathogenic rs132630268 GRCh37 Chromosome X, 48542796: 48542796
5 WAS NM_000377.2(WAS): c.257G> A (p.Arg86His) single nucleotide variant Pathogenic rs132630268 GRCh38 Chromosome X, 48684407: 48684407
6 WAS NM_000377.2(WAS): c.100C> T (p.Arg34Ter) single nucleotide variant Pathogenic rs132630271 GRCh37 Chromosome X, 48542342: 48542342
7 WAS NM_000377.2(WAS): c.100C> T (p.Arg34Ter) single nucleotide variant Pathogenic rs132630271 GRCh38 Chromosome X, 48683953: 48683953
8 WAS NM_000377.2(WAS): c.1A> T (p.Met1Leu) single nucleotide variant Pathogenic rs587776742 GRCh37 Chromosome X, 48542243: 48542243
9 WAS NM_000377.2(WAS): c.1A> T (p.Met1Leu) single nucleotide variant Pathogenic rs587776742 GRCh38 Chromosome X, 48683854: 48683854
10 WAS NM_000377.2(WAS): c.395_400dupACGAGG (p.Glu133_Ala134insAspGlu) duplication Pathogenic rs587776743 GRCh37 Chromosome X, 48544157: 48544162
11 WAS NM_000377.2(WAS): c.395_400dupACGAGG (p.Glu133_Ala134insAspGlu) duplication Pathogenic rs587776743 GRCh38 Chromosome X, 48685768: 48685773
12 WAS NM_000377.2(WAS): c.1097delG (p.Gly366Alafs) deletion Pathogenic rs587776744 GRCh37 Chromosome X, 48547214: 48547214
13 WAS NM_000377.2(WAS): c.1097delG (p.Gly366Alafs) deletion Pathogenic rs587776744 GRCh38 Chromosome X, 48688825: 48688825
14 WAS WAS, 15,800-BP DEL deletion Pathogenic
15 WAS WAS, IVS6DS, G-A, +5 single nucleotide variant Pathogenic
16 WAS WAS, IVS6AS, G-A, -1 single nucleotide variant Pathogenic
17 WAS WAS, IVS6DS, T-G, +2 single nucleotide variant Pathogenic
18 WAS NM_000377.2(WAS): c.11delG (p.Gly4Alafs) deletion Pathogenic rs587776745 GRCh37 Chromosome X, 48542253: 48542253
19 WAS NM_000377.2(WAS): c.11delG (p.Gly4Alafs) deletion Pathogenic rs587776745 GRCh38 Chromosome X, 48683864: 48683864
20 WAS WAS, 2-BP DEL, 73AC deletion Pathogenic
21 WAS WAS, 1-BP DEL, 758A deletion Pathogenic
22 WAS WAS, 1-BP DEL, CODON 241, C deletion Pathogenic
23 WAS NM_000377.2(WAS): c.310C> T (p.Gln104Ter) single nucleotide variant Likely pathogenic rs193922414 GRCh37 Chromosome X, 48543972: 48543972
24 WAS NM_000377.2(WAS): c.310C> T (p.Gln104Ter) single nucleotide variant Likely pathogenic rs193922414 GRCh38 Chromosome X, 48685583: 48685583
25 WAS NM_000377.2(WAS): c.37C> T (p.Arg13Ter) single nucleotide variant Pathogenic rs193922415 GRCh37 Chromosome X, 48542279: 48542279
26 WAS NM_000377.2(WAS): c.37C> T (p.Arg13Ter) single nucleotide variant Pathogenic rs193922415 GRCh38 Chromosome X, 48683890: 48683890
27 WAS NM_000377.2(WAS): c.763dupC (p.Gln255Profs) duplication Likely pathogenic rs193922416 GRCh37 Chromosome X, 48546471: 48546471
28 WAS NM_000377.2(WAS): c.763dupC (p.Gln255Profs) duplication Likely pathogenic rs193922416 GRCh38 Chromosome X, 48688082: 48688082
29 WAS NM_000377.2(WAS): c.273+11dupC duplication Benign rs58371799 GRCh37 Chromosome X, 48542823: 48542823
30 WAS NM_000377.2(WAS): c.273+11dupC duplication Benign rs58371799 GRCh38 Chromosome X, 48684434: 48684434
31 WAS NM_000377.2(WAS): c.873C> T (p.Tyr291=) single nucleotide variant Benign rs149123892 GRCh37 Chromosome X, 48546784: 48546784
32 WAS NM_000377.2(WAS): c.873C> T (p.Tyr291=) single nucleotide variant Benign rs149123892 GRCh38 Chromosome X, 48688395: 48688395
33 WAS NM_000377.2(WAS): c.777+1G> A single nucleotide variant Pathogenic rs1057517845 GRCh37 Chromosome X, 48546486: 48546486
34 WAS NM_000377.2(WAS): c.777+1G> A single nucleotide variant Pathogenic rs1057517845 GRCh38 Chromosome X, 48688097: 48688097
35 WAS NM_000377.2(WAS): c.90C> T (p.His30=) single nucleotide variant Benign rs148800063 GRCh38 Chromosome X, 48683943: 48683943
36 WAS NM_000377.2(WAS): c.90C> T (p.His30=) single nucleotide variant Benign rs148800063 GRCh37 Chromosome X, 48542332: 48542332
37 WAS NM_000377.2(WAS): c.852delC (p.Glu285Argfs) deletion Likely pathogenic GRCh37 Chromosome X, 48546763: 48546763
38 WAS NM_000377.2(WAS): c.852delC (p.Glu285Argfs) deletion Likely pathogenic GRCh38 Chromosome X, 48688374: 48688374
39 WAS NM_000377.2(WAS): c.290G> A (p.Trp97Ter) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 48543952: 48543952
40 WAS NM_000377.2(WAS): c.290G> A (p.Trp97Ter) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 48685563: 48685563
41 WAS NM_000377.2(WAS): c.553C> T (p.Gln185Ter) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 48544517: 48544517
42 WAS NM_000377.2(WAS): c.553C> T (p.Gln185Ter) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 48686128: 48686128
43 WAS NM_000377.2(WAS): c.1271dup (p.Leu425Profs) duplication Pathogenic GRCh37 Chromosome X, 48547388: 48547388
44 WAS NM_000377.2(WAS): c.1271dup (p.Leu425Profs) duplication Pathogenic GRCh38 Chromosome X, 48688999: 48688999
45 WAS NM_000377.2(WAS): c.271C> T (p.Gln91Ter) single nucleotide variant Pathogenic GRCh37 Chromosome X, 48542810: 48542810
46 WAS NM_000377.2(WAS): c.271C> T (p.Gln91Ter) single nucleotide variant Pathogenic GRCh38 Chromosome X, 48684421: 48684421
47 WAS NM_000377.2(WAS): c.897G> A (p.Gly299=) single nucleotide variant Likely benign rs782793103 GRCh38 Chromosome X, 48688419: 48688419
48 WAS NM_000377.2(WAS): c.897G> A (p.Gly299=) single nucleotide variant Likely benign rs782793103 GRCh37 Chromosome X, 48546808: 48546808
49 WAS NM_000377.2(WAS): c.91G> A (p.Glu31Lys) single nucleotide variant Pathogenic GRCh38 Chromosome X, 48683944: 48683944
50 WAS NM_000377.2(WAS): c.91G> A (p.Glu31Lys) single nucleotide variant Pathogenic GRCh37 Chromosome X, 48542333: 48542333

Expression for Wiskott-Aldrich Syndrome

Search GEO for disease gene expression data for Wiskott-Aldrich Syndrome.

Pathways for Wiskott-Aldrich Syndrome

Pathways related to Wiskott-Aldrich Syndrome according to KEGG:

37
# Name Kegg Source Accession
1 Endocytosis hsa04144
2 Regulation of actin cytoskeleton hsa04810

Pathways related to Wiskott-Aldrich Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.24 ACTR2 ACTR3 BTK CDC42 CTTN FYN
2
Show member pathways
14.07 ACTR2 ACTR3 BTK CDC42 FYN GRB2
3
Show member pathways
13.92 ACTR2 ACTR3 BTK CDC42 FYN GRB2
4
Show member pathways
13.79 ACTR2 ACTR3 BTK CDC42 FYN GRB2
5
Show member pathways
13.57 ACTR2 ACTR3 CDC42 FYN GRB2 NCK1
6
Show member pathways
13.48 ACTR2 ACTR3 BTK CDC42 FYN GRB2
7
Show member pathways
13.42 ACTR2 ACTR3 CTTN GRB2 SNX9 SRC
8
Show member pathways
13.39 ACTR2 ACTR3 BTK CDC42 FYN SRC
9
Show member pathways
13.1 ACTR2 ACTR3 CDC42 GRB2 SRC WAS
10
Show member pathways
13.04 ACTR2 ACTR3 CDC42 NCK1 SRC WAS
11
Show member pathways
12.99 ACTR2 ACTR3 CDC42 CTTN SRC WAS
12
Show member pathways
12.99 ACTR2 ACTR3 BTK CDC42 FYN GRB2
13
Show member pathways
12.92 CDC42 GRB2 SRC WAS WASL
14
Show member pathways
12.88 CDC42 CTTN FYN SRC WASF1
15
Show member pathways
12.84 BTK CDC42 FYN GRB2 SRC
16
Show member pathways
12.79 BTK FYN GRB2 NCK1 SRC
17
Show member pathways
12.78 CDC42 GRB2 NCK1 SRC WASL
18
Show member pathways
12.77 FYN GRB2 NCK1 SRC WASL
19
Show member pathways
12.76 ACTR2 ACTR3 CDC42 GRB2 SRC WAS
20 12.72 CDC42 SRC WAS WASF1 WASF2 WASL
21
Show member pathways
12.72 ACTR2 ACTR3 BTK CDC42 CTTN GRB2
22
Show member pathways
12.71 ACTR2 ACTR3 CDC42 FYN GRB2 NCK1
23
Show member pathways
12.69 BTK CDC42 FYN GRB2 SRC WIPF1
24
Show member pathways
12.64 ACTR2 ACTR3 CDC42 FYN GRB2 WAS
25
Show member pathways
12.62 BTK CDC42 FYN GRB2
26
Show member pathways
12.6 ACTR2 ACTR3 CDC42 CTTN FYN NCK1
27 12.57 ACTR2 ACTR3 CDC42 CTTN NCK1 WAS
28
Show member pathways
12.54 CDC42 FYN GRB2 NCK1 PSTPIP1 WAS
29
Show member pathways
12.54 FYN GRB2 WAS WASF1 WASF2 WASF3
30
Show member pathways
12.52 CDC42 FYN GRB2 SRC
31
Show member pathways
12.51 CDC42 GRB2 NCK1 SRC
32
Show member pathways
12.51 ACTR2 ACTR3 CDC42 FYN GRB2 WAS
33
Show member pathways
12.51 ACTR2 ACTR3 CTTN GRB2 SNX9 TRIP10
34
Show member pathways
12.49 CDC42 FYN GRB2 NCK1 SRC
35 12.49 CDC42 SRC WAS WASL WIPF1
36
Show member pathways
12.48 CDC42 FYN GRB2 SRC
37
Show member pathways
12.48 ACTR2 ACTR3 CDC42 FYN NCK1 SRC
38